CMA “ignored” evidence in excessive pricing case, Pfizer says
The UK’s Competition and Markets Authority “ignored” evidence in its decision that two drug companies’ prices were excessive, their defence counsel have argued.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10